Key result
An additional copy of the minor allele of SLCO1B1 rs4149056 was associated with an increased risk of cerivastatin-associated rhabdomyolysis (OR 1.89; 95% CI 1.40-2.56).
Why the study?
Are genetic variants associated with the risk of cerivastatin-associated rhabdomyolysis in statin users?
Population
185 rhabdomyolysis cases and 732 statin-using controls
Comparison
Genetic variants in candidate genes and… vs Statin-using controls without rhabdomyolysis
Design
Case-control
Authors
Loading...
SLCO1B1 variant may inform future statin myopathy risk models; leaves open clinical utility and generalizability beyond cerivastatin.
Case-Control (n=917)
Yes
Are genetic variants associated with the risk of cerivastatin-associated rhabdomyolysis in statin users?
Odds Ratio: 1.89 (95% CI 1.4–2.56)
p-value: p=0.002
Genetic variants in SLCO1B1 and RYR2 are modest risk factors for cerivastatin-associated rhabdomyolysis, but disabling variants in candidate genes do not fully explain the bimodal response.
Marciante et al. (2011) conducted a case-control in Cerivastatin-associated rhabdomyolysis (n=917). SLCO1B1 rs4149056 minor allele vs. Reference allele was evaluated on Risk of rhabdomyolysis (OR 1.89, 95% CI 1.40-2.56, p=0.002). An additional copy of the minor allele of SLCO1B1 rs4149056 was associated with an increased risk of cerivastatin-associated rhabdomyolysis (OR 1.89; 95% CI 1.40-2.56).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: